Exp Clin Endocrinol Diabetes 2009; 117(4): 165-169
DOI: 10.1055/s-2008-1080923
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Left Ventricular Function in Patients with Polycystic Ovary Syndrome: A Doppler Echocardiographic Study

A. Tekin 1 , G. Tekin 1 , Y. Çölkesen 1 , E. B. Kılıçdağ 2 , İ. Başhan 3 , A. T. Sezgin 1 , H. Müderrisoğlu 1
  • 1Department of Cardiology, Başkent University, Ankara, Turkey
  • 2Department of Obstetrics and Gynecology, Başkent University, Ankara, Turkey
  • 3Department of Family Medicine, Başkent University, Ankara, Turkey
Further Information

Publication History

received 18.01.2008 first decision 11.04.2008

accepted 03.06.2008

Publication Date:
30 September 2008 (online)

Abstract

Purpose: Polycystic ovary syndrome (PCOS) is frequently accompanied by the presence of cardiovascular risk factors. The aim of this study was to determine and compare the echocardiographic profiles of patients with PCOS with those of healthy subjects by using conventional echocardiographic methods and tissue Doppler imaging.

Methods: The study population consisted of 26 untreated patients with PCOS and 24 healthy controls who were mathced with respect to age and body mass index. In additon to standard two dimensional and M-mode measurements, color Doppler M-mode of left ventricular inflow propagation velocities (Vp), pulmonary venous flow measurements, transmitral valve flows and tissue Doppler imaging of the mitral annulus and basal wall were recorded.

Results: There were no significant differences between patients with PCOS and control subjects with respect to ejection fraction, mitral E/A ratio, deceleration time, isovolumic relaxation time, Vp and pulmonary venous velocities. The tissue Doppler profiles of patients with PCOS were also found to be similar to those of controls.

Conclusion: This study suggests that there are no significant differences in certain conventional and tissue Doppler echocardiographic measures of cardiac function between patients with PCOS and healthy control subjects.

References

  • 1 Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O’Keefe M, Ghazzi MN. PCOS/Troglitazone Study Group . Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.  J Clin Endocrinol Metab. 2001;  86 1626-1632
  • 2 Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure.  N Engl J Med. 2004;  351 1097-1105
  • 3 Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet.  Hum Reprod. 2003;  18 2289-2293
  • 4 Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women.  J Clin Endocrinol Metab. 1999;  84 1897-1899
  • 5 Celik O, Sahin I, Celik N, Hascalik S, Keskin L, Ozcan H, Uckan A, Kosar F. Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study.  Hum Reprod. 2007;  22 2992-2998
  • 6 Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.  Clin Endocrinol. 1992;  37 119-125
  • 7 Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives.  Atherosclerosis. 2006;  185 227-239
  • 8 Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women.  Acta Obstet Gynecol Scand. 1992;  71 599-604
  • 9 De Boeck BW, Cramer MJ, Oh JK, Aa RP van der, Jaarsma W. Spectral pulsed tissue Doppler imaging in diastole: a tool to increase our insight in and assessment of diastolic relaxation of the left ventricle.  Am Heart J. 2003;  146 411-419
  • 10 Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.  Diabetes. 1989;  38 1165-1174
  • 11 Ehrmann DA. Polycystic ovary syndrome.  N Engl J Med. 2005;  352 1223-1236
  • 12 Franks S. Are women with polycystic ovary syndrome at increased risk of cardiovascular disease? Too early to be sure, but not too early to act!.  Am J Med. 2001;  11 665-666
  • 13 Garcia MJ, Ares MA, Asher C, Rodriguez L, Vandervoort P, Thomas JD. An index of early left ventricular filling that combined with pulsed Doppler peak E velocity may estimate capillary wedge pressure.  J Am Coll Cardiol. 1997;  29 448-454
  • 14 Holte J, Gennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?.  Hum Reprod. 1996;  11 23-28
  • 15 Legro RS, Kunselman AR, Dunaif A. Prevalance and predictors of dyslipidemia in women with polycystic ovary syndrome.  Am J Med. 2001;  111 607-613
  • 16 Orio Jr F, Palomba S, Spinelli L, Cascella T, Tauchmanovà L, Zullo F, Lombardi G, Colao A. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study.  J Clin Endocrinol Metab. 2004;  89 3696-3701
  • 17 Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters.  Clin Endocrinol. 2001;  54 447-453
  • 18 Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston DG, Franks S. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries.  Clin Endocrinol. 1996;  44 277-284
  • 19 Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.  Clin Endocrinol. 1996;  45 623-629
  • 20 Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study.  J Clin Epidemiol. 1998;  51 415-422
  • 21 Tíras MB, Yalcìn R, Noyan V, Maral I, Yìldìrìm M, Dörtlemez O, Daya S. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome.  Hum Reprod. 1999;  14 1949-1952
  • 22 Topcu S, Caliskan M, Ozcimen EE, Tok D, Uckuyu A, Erdogan D, Gullu H, Yildirir A, Zeyneloglu H, Muderrisoglu H. Do young women with polycystic ovary syndrome show early evidence of preclinical coronary artery disease?.  Hum Reprod. 2006;  21 930-935
  • 23 Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1985;  61 946-951
  • 24 Yarali H, Yildirir A, Aybar F, Kabakçi G, Bükülmez O, Akgül E, Oto A. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome.  Fertil Steril. 2001;  76 511-516

Correspondence

A. TekinMD 

Department of Cardiology

Başkent University

Yüreğir

Adana

Turkey

Phone: +90/322/327 27 27

Fax: +90/322/327 12 76

Email: tekincardio@yahoo.com